US generics tariffs more negotiation tactic than real threat: Biocon’s Kiran Mazumdar-Shaw
The company, which is among the world’s top biosimilars manufacturers, remains in a wait-and-watch mode, while exploring partnerships for manufacturing in the US if required, Shaw said.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Wow
0
Sad
0
Angry
0
Comments (0)